ABEONA THERAPEUTICS INC.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
ABEO$2.46-3.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity for 2024 and 2023
Consolidated Statements of Stockholders’ Equity
(In thousands, except share amounts)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-in · Accumulated · Comprehensive · Stockholders’ | ||||||
| Shares | Amount | Capital | Deficit | Loss | Equity | |
| Balance at December 31, 2022 | 17,719,720 | $177 | $722,049 | $(695,336) | $(129) | $26,761 |
| Stock-based compensation expense | — | — | 4,768 | — | — | 4,768 |
| Issuance of common stock in connection with restricted share awards, net of cancellations and shares settled for tax withholding settlement | 1,859,869 | 18 | (200) | — | — | (182) |
| Issuance of common stock, net of offering costs under open market sale agreement (ATM) | 3,659,882 | 37 | 14,586 | — | — | 14,623 |
| Issuance of common stock, net of offering costs under direct placement offering | 3,284,407 | 33 | 22,948 | — | — | 22,981 |
| Net loss | — | — | — | (54,188) | — | (54,188) |
| Other comprehensive income | — | — | — | — | 63 | 63 |
| Balance at December 31, 2023 | 26,523,878 | $265 | $764,151 | $(749,524) | $(66) | $14,826 |
| Stock-based compensation expense | — | — | 6,628 | — | — | 6,628 |
| Issuance of common stock in connection with restricted share awards, net of cancellations and shares settled for tax withholding settlement | 1,780,713 | 19 | (545) | — | — | (526) |
| Issuance of common stock, net of offering costs under open market sale agreement (ATM) | 2,825,954 | 28 | 15,447 | — | — | 15,475 |
| Issuance of common stock in connection with public offering, net of offering costs | 12,285,056 | 123 | 70,030 | — | — | 70,153 |
| Issuance of common stock upon exercise of pre-funded warrants, net of shares settled | 2,228,490 | 22 | (22) | — | — | — |
| Reclassification of derivative liability | — | — | 1,135 | — | — | 1,135 |
| Net loss | — | — | — | (63,734) | — | (63,734) |
| Other comprehensive income | — | — | — | — | 74 | 74 |
| Balance at December 31, 2024 | 45,644,091 | $457 | $856,824 | $(813,258) | $8 | $44,031 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.